Physician profile
Erin E Corbin
NPI 1861652406
$2,098.76
in general payments reported to CMS, 2019-2025
34 companies · $124 in 2025
The $124 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $223 · 2021: $695 · 2022: $238 · 2023: $460 · 2024: $213 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $205.75 | 2021-2024 | Shingrix, Pediarix, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.49 | 2020-2024 | Xifaxan |
| Abbvie INC. | $194.91 | 2020-2021 | |
| Genentech USA, INC. | $167.51 | 2019-2022 | |
| Pfizer INC. | $166.42 | 2019-2025 | |
| Novo Nordisk INC | $153.01 | 2020-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $128.84 | 2021-2025 | Freestyle Libre 3 |
| Corium, LLC | $93.68 | 2023-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $78.63 | 2022-2024 | Qelbree, Qelbree |
| Amgen INC. | $70.75 | 2021-2023 | Prolia, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $62.95 | 2021 | |
| Dynavax Technologies Corporation | $50.76 | 2022-2024 | Heplisav-B |
| Medtronic, INC. | $49.81 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Nestle Healthcare Nutrition INC. | $48.43 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $46.64 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $45.96 | 2023-2024 | |
| Nabriva Therapeutics, Plc | $37.60 | 2021 | |
| Idorsia Pharmaceuticals US INC | $29.67 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $26.35 | 2020-2021 | |
| Inspire Medical Systems, INC. | $21.88 | 2023 | Inspire |
| Kaleo, INC. | $21.69 | 2020 | |
| Nevro Corp. | $21.36 | 2023 | Senza |
| Ultragenyx Pharmaceutical INC. | $19.56 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.94 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.38 | 2021 | |
| Aimmune Therapeutics, INC. | $17.46 | 2024 | |
| Novartis Pharmaceuticals Corporation | $16.69 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $15.35 | 2022 | |
| Exeltis, USA INC. | $14.60 | 2021 | |
| Dexcom, INC. | $13.59 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.37 | 2020 | |
| Amarin Pharma, INC. | $13.28 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.05 | 2021 | |
| Organon LLC | $8.40 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Corbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.